TrialDouble Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
Trial details
- Registry ID
- NCT04678830
- Phase
- Phase 2
Drug research
Leronlimab (700mg)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as PRO 140; Pro140
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19NCT04678830 | CytoDyn, Inc. | Phase 2 | Completed | 2021-06-05Actual |
| Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19NCT04347239 | CytoDyn, Inc. | Phase 2 | Completed | 2021-10-24Actual |
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
Trial details
- Registry ID
- NCT04347239
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |